Assembly Biosciences Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate Abi-4334 for the Treatment of Chronic Hepatitis B Virus Infection
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.